Metastatic colorectal cancer (mCRC) has a five-year relative survival rate of 14%. Most patients receive 5-FU (F) and folinic acid (FOL) combined with oxaliplatin (OX), …
GSK-3 is a serine/threonine kinase overexpressed in multiple tumor types and implicated in several oncogenic processes. GSK-3 inhibitor (GSK-3i) elraglusib (elra) has shown promising preclinical …